{"analyses":[{"ciLowerLimit":"0.615","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.979","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0324","paramType":"Hazard Ratio (HR)","paramValue":"0.776","statisticalComment":"Stratification factors include region, age, and WBC count at the time of diagnosis of AML.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Due to insufficient number of events, an estimate of the upper limit of the confidence interval could not be determined","groupId":"OG000","lowerLimit":"21.0","upperLimit":"NA","value":"31.9"},{"groupId":"OG001","lowerLimit":"13.2","upperLimit":"26.2","value":"15.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"271"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization until death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who were randomized to receive quizartinib treatment regimen.","id":"OG000","title":"Quizartinib"},{"description":"Participants who were randomized to receive placebo treatment regimen.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Overall survival was assessed in the Intent-to-Treat Analysis Set.","reportingStatus":"POSTED","timeFrame":"Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment","title":"Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","type":"PRIMARY","unitOfMeasure":"months"}